Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.
Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote